|Table of Contents|

Effect of residual urine volume on recurrence in patients with non-muscle invasive bladder cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 16
Page:
3066-3070
Research Field:
Publishing date:

Info

Title:
Effect of residual urine volume on recurrence in patients with non-muscle invasive bladder cancer
Author(s):
WAN Wenjie1; HOU Xiaona2; YANG Jinhui2; WANG Mingyue2; GAI Xinyu2; LIU Yonghui1; CHENG Bo2
1.Clinical Medical College of Weifang Medical University，Shandong Weifang 261053，China；2.Department of Urology Surgery， Shengli Oilfield Central Hospital，Shandong Dongying 257099，China.
Keywords:
residual urine volume; benign prostatic hyperplasia; non-muscle invasive bladder cancer; recurrence
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2023.16.023
Abstract:
Objective:To investigate the effect of urinary residual volume (RUV) induced by benign prostatic hyperplasia (BPH) on postoperative tumor recurrence in male patients with non-muscle invasive bladder cancer (NMIBC).Methods:113 male NMIBC patients who underwent transurethral resection of bladder tumor (TURBT) in the urology department of Shengli Oilfield Central Hospital from January 2018 to June 2020 were selected as the study subjects.The clinical and pathological data of patients were recorded,including the international prostate symptom score (IPSS),the maximum urinary flow rate (Qmax) and RUV.Kaplan-Meier method was used to analyze the relationship between RUV and postoperative tumor recurrence.Cox risk regression model was used to analyze the independent risk factors of tumor recurrence in male NMIBC patients after operation.Results:The average follow-up time of 113 male patients with NMIBC was (24.86±7.17) months.The number of tumor recurrence in the high RUV group and the low RUV group was 37 and 18,respectively.The rate of tumor recurrence in the high RUV group was higher than that in the low RUV group (P＜0.05).Kaplan-Meier analysis showed that the cumulative recurrence free survival rate of tumor in the high RUV group was lower than that in the low RUV group (P＜0.05).Cox risk regression model analysis showed that RUV was an independent risk factor for postoperative recurrence in male NMIBC patients (P＜0.05).Conclusion:High RUV can increase the risk of tumor recurrence in male NMIBC patients.

References:

［1］ SUNG H，FERLAY J，SIEGEL R，et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021,71(3):209-249.
［2］ SIEGEL R，MILLER K，FUCHS H，et al.Cancer statistics，2022 ［J］.Ca Cancer J Clin，2022,72(1):7-33.
［3］ LOBO N，AFFERI L，MOSCHINI M，et al.Epidemiology，screening，and prevention of bladder cancer ［J］.Eur Urol Oncol，2022,5(6):628-639.
［4］ RICHTERS A，ABEN K，KIEMENEY L.The global burden of urinary bladder cancer:an update ［J］.World J Urol，2020,38(8):1895-1904.
［5］ AWEDEW AF，HAN H，ABBASI B，et al.The global，regional，and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019:a systematic analysis for the Global Burden of Disease Study 2019 ［J］.The Lancet Healthy Longevity，2022,3(11):e754-e776.
［6］ AL-ZUBI MT，DEMOUR SA，AL-RAWASHDAH SF，et al.Does post-void residual urine volume affect potential recurrence risk for non-muscle invasive bladder cancer［J］.Future Sci OA，2023,8(9):823-829.
［7］ SYLVESTER R，VAN DER MEIJDEN A，OOSTERLINCK W，et al.Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials ［J］.Eur Urol，2006,49(3):466-470,discussion 475-477.
［8］ HAN M，MAISCH P，JUNG J，et al.Intravesical gemcitabine for non-muscle invasive bladder cancer ［J］.Cochrane Database Syst Rev，2021,6(6):CD009294.
［9］ KAMAT A，BRIGGMAN J，URBAUER D，et al.Cytokine panel for response to intravesical therapy (CyPRIT):nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin ［J］.Eur Urol，2016,69(2):197-200.
［10］ KAMAT A，PORTEN S.Myths and mysteries surrounding Bacillus Calmette-Guerin therapy for bladder cancer ［J］.Eur Urol，2014,65(2):267-269.
［11］ CUMBERBATCH M，JUBBER I，BLACK P，et al.Epidemiology of bladder cancer:a systematic review and contemporary update of risk factors in 2018 ［J］.Eur Urol，2018,74(6):784-795.
［12］ ZHOU J，LI L，LI X，et al.Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate-and high-risk non-muscleinvasive bladder cancer:a single-institution nonrandomized concurrent controlled trial ［J］.Int J Hyperthermia，2019,36(1):868-875.
［13］ BABJUK M，BOHLE A，BURGER M，et al.Eau guidelines on non-muscleinvasive urothelial carcinoma of the bladder:update 2016 ［J］.Eur Urol，2017,71(3):447-461.
［14］ RAY E，T O'BRIEN.Approaches to reducing recurrence in superficial bladder cancer ［J］.Eur Kidney Urol,2006,1:1-6.
［15］ RUAN Q，DING D，WANG B，et al.A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer［J］.Cancer Biol Med，2021,18(1):308-317.
［16］ LI S，ZHAO K，JIN Y，et al.Relapse and prognosis of non-muscle invasive bladder cancer after combined holrbt with sunitinib and tgc perfusion chemotherapy ［J］.Cancer Biother Radiopharm，2020,35(8):563-569.
［17］ EL-FALOUJI AI，SABRI DM，LOTFI NM，et al.Rapid detection of recurrent non-muscle invasive bladder cancer in urine using ATR-FTIR technology ［J］.Molecules，2022,27(24):8890-8902.
［18］ CUMBERBATCH M，ROTA M，CATTO J，et al.The role of tobacco smoke in bladder and kidney carcinogenesis:a comparison of exposures and meta-analysis of incidence and mortality risks ［J］.Eur Urol，2016,70(3):458-466.
［19］ STEVEN A，ROTH B，BIRKHAUSER F，et al.Re:benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients:a population-based cohort study using the national health insurance in Taiwan ［J］.The Journal of Urology，2014,191(1):58-59.
［20］ LIN Y，HOU C，JUANG H，et al.Association between bladder outlet obstruction and bladder cancer in patients with aging male ［J］.J Clin Med，2019,8(10):1550-1564.
［21］ MATSUMOTO S，SHIMIZU N，HANAI T，et al.Bladder outlet obstruction accelerates bladder carcinogenesis ［J］.BJU Int，2009,103(10):1436-1439.
［22］ JIANG X，CASTELAO J，GROSHEN S，et al.Water intake and bladder cancer risk in Los Angeles County ［J］.Int J Cancer，2008,123(7):1649-1656.
［23］ LUNNEY A，HAYNES A，SHARMA P，et al.Moderate or severe LUTS is associated with increased recurrence of non-muscle-invasive urothelial carcinoma of the bladder ［J］.Int Braz J Urol，2019,45(2):306-314.
［24］ UGURLU O，GONULALAN U，ADSAN O，et al.Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results ［J］.Urology，2007,70(1):55-59.
［25］ HAM W，KIM W，JEON H，et al.Long-term outcome of simultaneous transurethral resection of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and bladder outlet obstruction ［J］.J Urol，2009,181(4):1594-1599.
［26］ OELKE M，HOFNER K，JONAS U，et al.Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men:detrusor wall thickness，uroflowmetry，postvoid residual urine，and prostate volume ［J］.Eur Urol，2007,52(3):827-834.

Memo

Memo:
-
Last Update: 1900-01-01